As a diagnostic contrast agent, Xenetix 350 (iobitridol) is generally applied to help provide the diagnostic clarity considered relevant for managing conditions that present with distressing symptoms. It is applied in addressing conditions where functional stability becomes affected, supporting clinical assessment in scenarios where symptoms create noticeable physiological strain.

The agent is for diagnostic use only in procedures such as CT scans, conventional angiography, intravenous urography, and angiocardiography.

This agent is commonly used across conditions characterized by periods of heightened symptoms, and is relevant for easing symptom clusters that may become intense or disruptive. The supportive relief offered by a clear diagnosis helps maintain a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

“This application may assist with providing clear visual data for clinical assessment.”

---

Quick Fact: Relief for Symptom Burden This agent contributes to easing the overall symptom load. It is considered relevant in contexts involving heightened systemic burden for diagnostic purposes in conditions presenting with acute or unstable symptom patterns.

Regulatory References

1. TGA Approved Medicine Xenetix 350

Contraindications and Eligibility Rules for Xenetix 350

The eligibility for Xenetix 350 (Iobitridol) is strictly defined by regulatory guidelines based on patient health status and demographics. The medicine is contraindicated and must not be used in patients with known hypersensitivity to Iobitridol or any of its ingredients, a history of a major immediate reaction to a previous Xenetix injection, or active manifest thyrotoxicosis (severe hyperthyroidism).

Patient Group	Eligibility Status (Official Labeling)
Allergy/Reaction History	Contraindicated in case of major immediate or delayed cutaneous reaction to Iobitridol.
Endocrine Status	Contraindicated in manifest thyrotoxicosis; caution required with goitre or history of dysthyroidism.
Metformin Users	Contraindicated if the patient has abnormal renal function. Suspension of metformin is required for at least 48 hours after injection if renal function is normal.
Pregnancy	Preferable to avoid as a precautionary measure, though use may be justifiable after careful risk evaluation. Hysterosalpingography is contraindicated during pregnancy.
Lactation	Advisable to suspend breastfeeding for 24 hours after administration.
Severe Organ Impairment	Caution is required in patients with severe renal or hepatic failure.
Age Groups	Approved for adults and children, but specific precautions (e.g., hydration) apply to the elderly and neonates.

The official labeling establishes these clear boundaries and conditional restrictions to guide the use of this diagnostic agent.

Interactions with other medicines and products

The interaction profile for Xenetix 350 (Iobitridol) is defined by mandatory timing rules and specific restrictions related to systemic effects and organ function, as stated in regulatory documents.

Mandatory Timing and Separation Requirements

Treatment with the medicine Metformin must be formally suspended before contrast agent injection and for a minimum of 48 hours after the procedure, or until normal kidney function is confirmed to be restored. This restriction is due to the risk of lactic acidosis if the patient experiences functional kidney impairment. Additionally, no other medication should be injected in the same syringe to prevent chemical and physical incompatibility. The agent's iodine content interferes with diagnostic and therapeutic procedures using radioactive iodine, requiring a necessary delay until urinary iodine levels normalize.

Official Interaction Restrictions

Co-administration with Diuretics should be approached with caution as this combination may increase the risk of acute kidney failure, especially in a dehydrated state. The use of Iobitridol with other nephrotoxic medicines (such as aminosides, high-dose methotrexate, or certain antivirals) is advised against due to the potential to induce or worsen renal insufficiency. A pharmacodynamic interaction exists with Beta-adrenergic blocking agents (beta-blockers), which may increase the risk of moderate to severe anaphylactoid reactions and hypotension during the procedure. The use of Metformin is formally contraindicated in patients with pre-existing abnormal renal function.

The function of Xenetix 350 (Iobitridol) relies on a physicochemical mechanism, not the modulation of biological receptors or enzymes. Its activity is centered on the iodine atoms covalently integrated into the molecule, which serve as physical targets. This high-density element efficiently absorbs X-ray photons through the photoelectric effect, a process called X-ray attenuation that reduces the radiation passing through the medium. This interaction results in the generation of radiopacity. This domain is necessary for the visibility of the agent, creating a sharp, temporary density gradient against surrounding soft tissues.

The visualization effect is entirely dependent on the hemodynamic pathway—the rapid and efficient distribution of the water-soluble Iobitridol throughout the vascular lumen and extracellular space. This transient presence creates an area of extremely high atomic density in the blood vessels, resulting in an immediate increase in visualization. The mechanism is inherently time-limited and subject to concentration dependency because the effect quickly diminishes as the agent is physiologically diluted by blood flow and undergoes rapid renal excretion (washout).

Official Administration Guidelines

Xenetix 350 (Iobitridol 350 mg I/mL solution) is a non-ionic, iodinated contrast agent administered by healthcare professionals for diagnostic imaging procedures. Its administration is standardized to ensure procedural safety and efficacy.

---

Administration Scope

Instruction Entity	Official Requirement
Route of Administration	Intravascular (Intravenous or Intra-arterial injection). Specific procedures may utilize Intra-articular or Intra-uterine routes.
Dosing Schedule	Highly individualized, calculated based on the type of radiological examination, patient's weight, and renal function. The lowest effective dose must be used to achieve adequate visualization.
Preparation	The solution must be warmed to body temperature (37 C) before injection.
Hydration	Adequate hydration must be ensured before and after administration.

---

Procedural Structure and Dosing Rules

1. Dose Calculation: The dose is precisely determined (often in mL/kg) according to the procedure (e.g., CT, Angiography). Example adult dose ranges for IV Urography typically start at 1 mL/kg.
2. Rate of Injection: Administration occurs at a controlled speed (rate of injection), which is adjusted based on the examination type (e.g., bolus for rapid CT scanning).
3. Age-Specific Rules: Dosing for children is weight-based and often requires higher relative doses ( mL/kg) in infants to compensate for the lower concentrating ability of their kidneys.
4. Post-Procedure: The patient must be monitored for at least 30 minutes following administration for delayed reactions.

These administration instructions define the technical parameters necessary for the safe and correct use of Xenetix 350 in diagnostic medicine.

Research Evidence / Overview of Studies for Xenetix 350

Evidence for Use in Specialized Angiography and CT Imaging

Research exploring Xenetix 350 in specialized cardiac imaging, such as Coronary CT Angiography (CCTA), has primarily used randomized, controlled, double-blind trials focused on adult patients. Researchers examined technical outcomes, including the rate of evaluable CT scans (scans meeting predefined image criteria) and Signal-to-Noise Ratio (SNR). These trials were designed to examine the agent’s technical performance when compared to other contrast media, including those with differing iodine concentrations.

Evidence for Use in General Diagnostic Procedures

The research base exploring this agent in general radiology, including whole-body CT scans and conventional angiography, relies on randomized trials and very large post-marketing surveillance studies involving tens of thousands of patients. These observational studies monitored the overall diagnostic possibility and global image quality observed, showing patterns related to how frequently a clinical assessment was possible in diverse populations.

Evidence in Specialized Patient Groups

Research has explored the agent in specific patient groups, including controlled clinical trials in the pediatric population for brain and body CT examinations. Large post-marketing studies also provide evidence describing use in broad cohorts that included patients with pre-existing risk factors or comorbid conditions.

Long-Term Evidence and Follow-Up Duration

The majority of research focuses on short-term outcomes, with measurements typically reported within 24 hours of the agent being administered. This aligns with the agent’s role, where image evaluation occurs immediately. Consequently, there is limited information for long-term outcomes or durability of findings that extend beyond the initial diagnostic assessment.

What Research Gaps and Uncertainties Exist

Many of the randomized trials were designed to examine the agent’s performance relative to other established contrast agents, with a focus on non-inferiority endpoints. The evidence gathered is specific to the populations included in the studies, and information for certain groups remains limited regarding long-term use or repeated exposure over time.

Key Studies & References

1. TGA Approved Medicine Xenetix 350 (Iobitridol 767.8g/767.8mg/mL corresponding to iodine 350mg/mL solution for injection, France)
2. Safety and tolerability of iobitridol in children: a randomized, controlled, double-blind study.

Common questions about Xenetix 350 (FAQ)

---

Q: How long does the contrast effect of Xenetix 350 last in the body?

Regulatory information indicates that the active ingredient, Iobitridol, has an elimination half-life of approximately 1.8 to 2.3 hours in people with normal kidney function. This indicates that the elimination of the active substance from the body is relatively quick. The contrast agent is nearly completely removed by the kidneys within 24 hours of administration.

---

Q: Why do I need to be well-hydrated before receiving Xenetix 350?

Official administration guidelines state that adequate hydration must be ensured both before and after the procedure. This is a crucial preventive measure used to support kidney function, as contrast agents can cause a temporary change in kidney function, especially in patients who are dehydrated.

---

Q: What are the known interactions between Xenetix 350 and the diabetes medication Metformin?

Regulatory documents describe a mandatory timing restriction related to Metformin. The use of an iodinated contrast agent carries a risk of a rare, serious condition called lactic acidosis, especially if the patient develops kidney impairment. The regulatory guidance specifies that Metformin treatment is typically suspended before the injection and for a minimum of 48 hours afterward, or until normal kidney function is confirmed.

---

Q: Are there concerns about combining diuretics with a Xenetix 350 injection?

Official product information advises caution when co-administering diuretics (medicines that increase urine production). This combination may increase the risk of acute kidney failure, particularly in a dehydrated state. If a diuretic is being used, official guidance indicates that saline rehydration may be necessary.

---

Q: Is it true that Xenetix 350 can interfere with future thyroid function tests?

Yes, because Xenetix 350 contains iodine, its administration can temporarily interfere with diagnostic and therapeutic procedures that use radioactive iodine, such as certain thyroid tests. This interference lasts until the excess iodine is eliminated from the body. The healthcare team manages the timing of contrast administration relative to any radioactive iodine procedures.

---

Q: Is Xenetix 350 safe for newborns or premature infants?

The product is approved for use in both adults and children, but special precautions are necessary for newborns and infants. Safety notes indicate a documented risk of transient thyroid suppression (temporary reduction of thyroid activity) in this age group, requiring careful monitoring by the healthcare professional.

---

Q: What is the concern about using Xenetix 350 in patients with both liver and kidney problems?

Regulatory information advises that caution is required in patients with both severe renal (kidney) and hepatic (liver) impairment. The need for caution stems from the fact that if both the body’s main elimination pathways are significantly compromised, there is an increased risk of the contrast agent being retained in the body for a longer period.

---

Q: What are the characteristics of a low osmolar contrast agent like Xenetix 350?

Xenetix 350 is classified as a low osmolar, non-ionic X-ray contrast medium. This characteristic is associated with minimizing discomfort during injection and reducing the risk of certain adverse effects compared to contrast agents with a higher osmolarity.

---

Q: What research evidence supports the use of Xenetix 350 in the pediatric population?

Clinical trials and research studies have examined the use of Xenetix 350 in the pediatric population, specifically for brain and body CT examinations. This evidence describes the agent's technical performance and safety profile in this specific group.

---

Q: How is Xenetix 350 different from older, ionic contrast dyes?

Xenetix 350 is a modern, non-ionic contrast agent, while older dyes were often ionic. This non-ionic structure, along with its low osmolarity, is associated with a lower risk of adverse hemodynamic events (related to blood flow) and may cause less discomfort during the injection procedure.

---

Q: What is extravasation and what is the general risk with Xenetix 350?

Extravasation is the complication where the contrast agent leaks out of the vein into the surrounding soft tissue during injection. Official risk management documents note that while most occurrences are minor, it is a known, non-exceptional complication. Rare, severe injuries such as tissue necrosis can occur, which is why careful administration is required.

---

Q: Can Xenetix 350 be safely used in patients undergoing hemodialysis?

For patients with existing kidney failure, official information notes that the active ingredient Iobitridol is removable from the body using hemodialysis. This indicates that if administration is necessary for diagnosis, the contrast agent is removable from the system using the dialysis procedure.

---

Q: Are there different versions of Xenetix (like Xenetix 300) and how do they differ from Xenetix 350?

Yes, Xenetix is available in different concentrations, such as Xenetix 250, 300, and 350. The number indicates the precise concentration of iodine in milligrams per milliliter of solution. The specific concentration chosen by the healthcare provider is based on the type of examination, the region being targeted, and the necessary degree of contrast.

---

Q: What are the rules regarding the use of Xenetix 350 in the elderly population?

Specific precautions are necessary for elderly patients because they may have age-related decline in kidney function. Since the body eliminates the contrast agent through the kidneys, professionals pay close attention to the patient’s hydration and kidney status during administration.

---

Q: Can an individual with known myasthenia gravis receive Xenetix 350?

Regulatory documents indicate that the administration of an iodinated contrast agent may worsen the symptoms of myasthenia gravis, a neuromuscular disease. Therefore, specific caution and careful monitoring are required for patients with this pre-existing condition.

---

Q: Does anxiety or nervousness affect the risk profile of Xenetix 350 administration?

Yes, official warnings note that patient anxiety, fear, or agitation related to the procedure may intensify potential side effects of the iodinated contrast agent. It is noted that clinical staff may take precautions to help manage patient stress before and during administration.

---

Q: Why is Xenetix 350 sometimes restricted for people with sickle cell disease?

Regulatory product information advises that special care must be taken in patients with sickle-cell disease. This is a necessary precaution to prevent potential adverse outcomes in this specific, at-risk patient group when receiving an iodinated contrast agent.

---

Q: What are the special considerations for patients with heart failure or other heart problems?

The risk of cardiovascular reactions is noted to be increased after injection in patients with existing severe cardiovascular diseases, heart failure, or coronary insufficiency. Intravascular injection may also cause complications like pulmonary edema in patients with manifest or incipient heart failure.

---

Q: Are there concerns about combining other nephrotoxic medicines with Xenetix 350?

Yes, co-administration with other nephrotoxic medicines (drugs that can be harmful to the kidneys) is generally advised against. This is because this combination may induce or worsen kidney insufficiency. If the combination is unavoidable, laboratory monitoring of kidney function must be intensified.

---

Q: What is the general elimination process of Xenetix 350 from the body?

After injection, the contrast agent is not metabolized and travels through the body's vascular system. It is then eliminated solely in its unchanged form by the kidneys through a process called glomerular filtration. In individuals with normal kidney function, this process typically results in complete removal within 24 to 48 hours.

---

Q: How is the administration of Xenetix 350 related to a patient's kidney function test results?

The patient's renal function status is a necessary consideration for administration. The healthcare team must take the patient's kidney function test results into account when planning the procedure and when applying certain interaction rules, such as the suspension of Metformin.

How to Store and Dispose of Xenetix 350

The storage and disposal of Xenetix 350 (Iobitridol) solution for injection must strictly follow the official product labeling to maintain its stability and integrity.

---

Storage Requirements

• Temperature: Store the medicinal product at a temperature of less than 30°C. Stability studies support storage at temperatures of less than 35°C.
• Protection: Keep the container in the outer carton to protect the solution from light.
• Child Safety: This medicine must be kept out of the reach and sight of children.
• Stability: The product is for single use only. The unopened shelf-life is three years. For bags, do not remove the container from the overwrap until immediately before use.

---

Disposal Instructions

• Unused Product: Any remaining contents in a single-use container, or contents unused after 24 hours of first opening (when used with automated systems), must be discarded.
• Waste Handling: Disposal of all unused product and waste material must be conducted in accordance with local requirements.